relapsed and/or refractory multiple myeloma
Showing 1 - 25 of >10,000
Relapsed and/or Refractory Multiple Myeloma Trial in Köln (BMS-986453, Fludarabine, Cyclophosphamide)
Not yet recruiting
- Relapsed and/or Refractory Multiple Myeloma
- BMS-986453
- +2 more
-
Köln, GermanyLocal Institution - 0017
Dec 4, 2023
Belantamab Mafodotin Care Patterns in Relapsed and/or Refractory
Not yet recruiting
- Multiple Myeloma
-
Durham, North CarolinaDuke University Medical Center
Aug 8, 2023
Relapsed and/or Refractory Multiple Myeloma, Plasma Cell Leukemia in Relapse Trial in Shanghai (Biological)
Recruiting
- Relapsed and/or Refractory Multiple Myeloma
- Plasma Cell Leukemia in Relapse
- Biological
-
Shanghai, Shanghai, ChinaShanghai Tongji Hospital
May 29, 2023
Relapsed and/or Refractory Multiple Myeloma Trial in China (ICP-490)
Not yet recruiting
- Relapsed and/or Refractory Multiple Myeloma
-
Beijing, Beijing, China
- +4 more
Jan 30, 2023
Relapsed/Refractory Multiple Myeloma Trial (Isatuximab, Carfilzomib, Dexamethasone)
Not yet recruiting
- Relapsed/Refractory Multiple Myeloma
- Isatuximab
- +3 more
- (no location specified)
Feb 3, 2023
Relapsed and/or Refractory Multiple Myeloma Trial (CT0591CP Cells)
Not yet recruiting
- Relapsed and/or Refractory Multiple Myeloma
- CT0591CP Cells
- (no location specified)
Aug 2, 2022
Long-term KRd in Relapsed and/or Refractory Multiple Myeloma
Not yet recruiting
- Multiple Myeloma in Relapse
- Multiple Myeloma, Refractory
- Carfilzomib
- +2 more
- (no location specified)
Aug 8, 2022
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial (Carfilzomib, Cyclophosphamide, Dexamethasone)
Not yet recruiting
- Multiple Myeloma in Relapse
- Multiple Myeloma, Refractory
- Carfilzomib
- +2 more
- (no location specified)
Jun 8, 2023
Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Relapsed and/or Refractory Multiple Myeloma (RRMM) Trial run by the
Not yet recruiting
- Multiple Myeloma
- +2 more
- 18F-fluciclovine injection
- 18F-FDG PET/CT
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Oct 31, 2023
Multiple Myeloma Trial (BCMA-TGFß CAR-T cells (0.75 x10^6 cells/kg), BCMA-TGFß CAR-T cells (1 x 10^6 cells/kg), BCMA-TGFß CAR-T
Not yet recruiting
- Multiple Myeloma
- BCMA-TGFβ CAR-T cells (0.75 x10^6 cells/kg)
- +3 more
- (no location specified)
Jul 28, 2023
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Rochester (Bortezomib, Metformin Hydrochloride,
Active, not recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Bortezomib
- +2 more
-
Jacksonville, Florida
- +1 more
Jan 5, 2023
Relapsed and/or Refractory Multiple Myeloma Trial in Worldwide (AMG 420)
Completed
- Relapsed and/or Refractory Multiple Myeloma
- AMG 420
-
Park Ridge, Illinois
- +9 more
Dec 1, 2022
Refractory Multiple Myeloma, Relapse Multiple Myeloma Trial in Milwaukee (Belantamab mafodotin)
Recruiting
- Refractory Multiple Myeloma
- Relapse Multiple Myeloma
- Belantamab mafodotin
-
Milwaukee, WisconsinFroedtert & the Medical College of Wisconsin
Aug 3, 2022
Quality of Life in Relapsed and/or Refractory Multiple Myeloma
Active, not recruiting
- Multiple Myeloma
-
Morrisville, North CarolinaLocal Institution
May 12, 2022
Multiple Myeloma Trial in Beijing, Nanjing, Tianjin (Isatuximab SAR650984)
Active, not recruiting
- Multiple Myeloma
- Isatuximab SAR650984
-
Beijing, China
- +2 more
Aug 22, 2022
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Hangzhou (APRIL CAR-T cells)
Recruiting
- Multiple Myeloma in Relapse
- Multiple Myeloma, Refractory
- APRIL CAR-T cells
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital,College of Medicine, Zhejiang Univ
May 3, 2022
Multiple Myeloma Trial in Beijing, Suzhou (CAR-BCMA T Cells)
Recruiting
- Multiple Myeloma
- CAR-BCMA T Cells
-
Beijing, Beijing, China
- +1 more
Jan 26, 2023
Multiple Myeloma Trial in Chicago, Boston, Milwaukee (PHE885)
Recruiting
- Multiple Myeloma
- PHE885
-
Chicago, Illinois
- +4 more
Jul 28, 2022
Multiple Myeloma Trial in Torino (Carfilzomib, Pomalidomide, Dexamethasone)
Active, not recruiting
- Multiple Myeloma
- Carfilzomib
- +2 more
-
Torino, ItalyDipartimento di Biotecnologie Molecolari e Scienze per la Salute
Mar 24, 2022
Relapsed or Refractory Multiple Myeloma Trial (Forimtamig, Carfilzomib, Daratumumab)
Not yet recruiting
- Relapsed or Refractory Multiple Myeloma
- Forimtamig
- +2 more
- (no location specified)
Sep 20, 2023
Multiple Myeloma Trial (CM313 injection)
Not yet recruiting
- Multiple Myeloma
- CM313 injection
- (no location specified)
Nov 6, 2023
Multiple Myeloma (MM) Trial in Japan (OPC-415)
Recruiting
- Multiple Myeloma (MM)
- OPC-415
-
Isehara-shi, Japan
- +4 more
Apr 20, 2022